Who is sponsoring NCT02951026?

NCT02951026 is sponsored by Biosplice Therapeutics, Inc..

What drugs are being tested in NCT02951026?

Interventions in NCT02951026: Not applicable (no therapy is administered as part of this study).

What condition does NCT02951026 study?

NCT02951026 studies Osteoarthritis.

Is NCT02951026 still recruiting?

NCT02951026 is currently completed. Last updated 17 April 2020.

Last reviewed 2020-04-17 · How we verify

NCT02951026

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Observational Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis

Completed Last updated 17 April 2020

What this trial tests

trial testing Not applicable (no therapy is administered as part of this study) in Osteoarthritis in 703 participants. Completed in 31 October 2019.

Timeline

19 September 2016

Primary endpoint
31 October 2019

31 October 2019

Quick facts

Lead sponsor	Biosplice Therapeutics, Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	703
Start date	19 September 2016
Primary completion	31 October 2019
Estimated completion	31 October 2019
Sites	62 locations across United States

Drugs / interventions tested

Not applicable (no therapy is administered as part of this study)

Conditions studied

Osteoarthritis — all drugs for Osteoarthritis →

Sponsor

Biosplice Therapeutics, Inc. — full company profile →

Who can join

Adults 40 to 80, any sex, with Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This long-term extension study is designed to monitor the long-term safety, tolerability, and efficacy of treatment of SM04690 or placebo previously injected in the target knee joints of subjects with moderately to severely symptomatic osteoarthritis (OA) from a Samumed-sponsored SM04690-OA phase 2 or phase 3 study. No additional SM04690 or placebo therapy will be administered in this study.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Evaluation of Safety and Efficacy of a Single Lorecivivint Injection in Patients with Knee Osteoarthritis: A Multicenter, Observational Extension Trial.
Swearingen CJ, Tambiah JRS, Simsek I, Ghandehari H, et al · · 2025 · cited 4× · PMID 39755925 · DOI 10.1007/s40744-024-00731-9
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2021): Oral Communication Abstracts
· 2021

Verify or expand the search:

Other recruiting trials for Osteoarthritis

Currently open trials in the same condition.

NCT07404891 — Clinical Trial on the Efficacy and Safety of ALT001 in Osteoarthritis · NA · recruiting
NCT07118501 — A Prospective, Post-Market, Clinical Follow-up Study of the Incompass™ Total Ankle System · recruiting
NCT06631638 — EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN)) · NA · recruiting
NCT07198750 — "Bimodal vs Unimodal High-Intensity Pulsed Electromagnetic Field Therapy in Older Adults With Knee Osteoarthritis" · NA · recruiting
NCT07006714 — Preoperative Correction of Vitamin D Deficiency in Total Joint Arthroplasty (TJA) · Phase 4 · active not recruiting

Other Biosplice Therapeutics, Inc. trials

Trials by the same sponsor.

NCT05603754 — A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatm · Phase 3 · completed
NCT05084859 — A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With H · Phase 1 · terminated
NCT04931667 — 3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis · Phase 3 · terminated
NCT04598542 — Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers · Phase 1 · completed
NCT04520607 — A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02951026 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biosplice Therapeutics, Inc.
Last refreshed: 17 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02951026.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing